Allosteric and orthosteric pharmacology of cannabidiol and cannabidiol‐dimethylheptyl at the type 1 and type 2 cannabinoid receptors
British Journal of Pharmacology2018Vol. 176(10), pp. 1455–1469
Citations Over TimeTop 1% of 2018 papers
Mylyne Tham, Orhan Yılmaz, Mariam Alaverdashvili, Michael E. Kelly, Eileen M. Denovan‐Wright, Robert B. Laprairie
Abstract
This article is part of a themed section on 8th European Workshop on Cannabinoid Research. To view the other articles in this section visit http://onlinelibrary.wiley.com/doi/10.1111/bph.v176.10/issuetoc.
Related Papers
- → In vivo and in vitro treatment with the synthetic cannabinoid CP55,940 decreases the in vitro migration of macrophages in the rat: involvement of both CB1 and CB2 receptors(2000)123 cited
- → (+)-Cannabidiol analogues which bind cannabinoid receptors but exert peripheral activity only(2004)59 cited
- → 4-Oxo-1,4-dihydropyridines as Selective CB2Cannabinoid Receptor Ligands: Structural Insights into the Design of a Novel Inverse Agonist Series(2010)33 cited
- → Characterisation of inverse agonism of the orphan-G protein-coupled receptor GPR52 by cannabinoid ligands Cannabidiol and O-1918(2021)7 cited
- → Correction to: CB 1 Allosteric Modulator Org27569 Is an Antagonist/Inverse Agonist of ERK1/2 Signaling, by Gamage TF, Anderson JC, and Abood ME. Cannabis Cannabinoid Res. 2016;1(1):272–280. DOI: 10.1089/can.2016.0028(2019)